Donald Fuller, M.D., a radiation oncologist from Genesis Healthcare in San Diego, presented findings from a multi-center study of 260 patients with low and intermediate-risk prostate cancer treated using CyberKnife SBRT at 17 institutions, using an approach that emulates the dosimetry of high dose rate (HDR) brachytherapy.
Patients were followed for up to 48 months with a median follow-up of 24 months, and found to have disease-free survival of 98.5 percent, as updated during his presentation. Urinary and rectal toxicities reported at a minimum 1 year follow-up were in line with outcomes of traditional radiation therapy and erectile function returned to baseline by 3 years, with minimal disruption after treatment.
"These findings should encourage men to explore CyberKnife SBRT as a viable alternative to surgery or other radiation treatments, such as brachytherapy and intensity-modulated radiation therapy," said Dr. Fuller. "Findings to date indicate we may be able to minimize the undesirable side effects typically associated with other treatment modalities and help to preserve patients' quality of life during and after prostate cancer treatment."
Additionally, seven posters highlighting CyberKnife prostate SBRT experience were presented by researchers from the University of California San Francisco, Georgetown University Hospital, and Winthrop University Hospital, as well as additional research from Flushing Radiation Oncology and Swedish Cancer Institute in Seattle, further supporting the maturing body of prostate SBRT evidence.About Accuray Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is the premier radiation oncology company that develops, manufactures and sells personalized innovative treatment solutions that set the standard of care, with the aim of helping patients live longer, better lives. The Company's leading edge technologies – the CyberKnife and TomoTherapy Systems – are designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image guided radiation therapy, and adaptive radiation therapy. To date 642 systems have been installed in leading hospitals around the world. For more information, please visit www.accuray.com. Safe Harbor Statement Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical results and patient outcomes, and the Company's leadership position in radiation oncology innovation. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including risks detailed from time to time under the heading "Risk Factors" in the company's report on Form 10-K filed on September 10, 2012. Forward-looking statements speak only as of the date the statements are made and are based on information available to the Company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The Company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not place undue reliance on any forward-looking statements. SOURCE Accuray Incorporated
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts